47 completed, 3 terminated, 2 not yet recruiting, 2 recruiting. 13 Phase 3, 10 Phase 4, 7 Phase 1, 6 Phase 2, 2 Not applicable.
Follow F8 protein, human: new trials by email Literature Review of F8 protein, human trials Research Report on F8 protein, human
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Post Approval Phase 4 Study to Learn More About How Safe Octocog Alfa is, and How Well it Works in Patients With Severe Hemophilia A in India Octocog alfa - Severe Hemophilia A | Not yet recruiting | Bayer | 30 | 2027-04-05 | 2026-10-21 | |
| A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD) VONVENDI, ADVATE - Von Willebrand Disease (VWD) | Phase 3 | Recruiting | Takeda | 20 | 2025-10-13 | 2026-01-08 |
| Low Dose Emicizumab vs Low Dose Factor VIII in Prophylaxis in Hemophilia A Patients Emicizumab Injection, Factor VIII (FVIII) - Hemophilia A | Phase 2 / Phase 3 | Not yet recruiting | Dhaka Medical College | 20 | 2025-06-01 | 2025-04-22 |
| A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD) Vonicog Alfa, ADVATE - Von Willebrand Disease (VWD) | Phase 3 | Recruiting | Takeda | 24 | 2024-11-06 | 2026-09-09 |
| Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A Efanesoctocog alfa, Octocog alfa, Rurioctocog alfa pegol - Hemophilia A | Phase 1 | Completed | Sanofi | 13 | 2021-08-11 | 2025-09-18 |
| A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 1, Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 2, Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 3 - Hemophilia A | Phase 4 | Completed | Bayer | 45 | 2020-09-22 | 2025-04-18 |
| Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Hemophilia A Patients Moroctocog-alfa (AF-CC) - Hemophilia A | Phase 4 | Completed | Pfizer | 50 | 2020-01-25 | 2021-05-03 |
| Pharmacokinetics Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A. Xyntha, Recombinant Coagulation Factor VIII Injection - Hemophilia A | Phase 1 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 24 | 2019-05-08 | 2019-08-19 |
| A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD) rVWF, rFVIII - Von Willebrand Disease (VWD) | Phase 3 | Completed | Baxalta now part of Shire | 38 | 2019-04-01 | 2025-09-03 |
| A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD) Vonicog alfa, Antihemophilic Factor (Recombinant) - Von Willebrand Disease | Phase 3 | Completed | Baxalta now part of Shire | 47 | 2017-11-06 | 2026-05-15 |
| Drug Use Investigation of Kovaltry in Hemophilia A Patients Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973) - Hemophilia A | Completed | Bayer | 230 | 2016-11-30 | 2026-09-09 | |
| Pharmacokinetic Characterization of the Hemophilia A Population in Spain Using myPKFiT® octocog alfa, rurioctocog alfa pegol - Hemophilia A, Hemophilia | Completed | Spanish Society of Thrombosis and Haemostasis | 50 | 2016-11-11 | 2023-06-08 | |
| Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973 - Hemophilia A, Congenital | Completed | Bayer | 313 | 2016-10-14 | 2023-11-07 | |
| Pharmacokinetic Study of SCT800 in Previously Treated Patients With Hemophilia A SCT800, Xyntha - Hemophilia A | Phase 1 | Unknown | Sinocelltech Ltd. | 16 | 2016-09-01 | 2016-09-02 |
| Extension at 10 Years of the: "Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A." Recombinant Factor VIII (Kogenate FS, BAY14-2222) - Hemophilia A | Completed | Bayer | 43 | 2016-04-14 | 2020-11-18 | |
| BAX 826 Dose-Escalation Safety Study BAX 826, Octocog alfa - Hemophilia A | Phase 1 | Completed | Baxalta now part of Shire | 40 | 2016-03-03 | 2021-05-25 |
| Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A Octocog alfa (recombinant human coagulation factor VIII) - Hemophilia A | Completed | Baxalta now part of Shire | 21 | 2015-12-23 | 2021-03-17 | |
| ATHN 2: Factor Switching Study Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013, Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013 - Hemophilia | Completed | American Thrombosis and Hemostasis Network | 310 | 2015-09-01 | 2021-12-09 | |
| Weight-based Dosing in Hemophilia A rFVIII - Hemophilia | Phase 2 | Terminated | Craig Seaman | 30 | 2015-09-01 | 2020-09-25 |
| PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A Intravenous infusions of Xyntha - Hemophilia A | Phase 4 | Completed | Pfizer | 85 | 2015-04-01 | 2017-04-04 |
Showing 20 of 57. Sign in to see all of them.
Hemophilia A (52) · von Willebrand Diseases (4) · Blood Coagulation Disorders (3) · Hemostatic Disorders (3) · Hematologic Diseases (2) · Hemarthrosis (1) · Hemophilia B (1) · Hemorrhage (1) · Thrombosis (1)
Bayer (26) · Baxalta now part of Shire (9) · Pfizer (6) · Takeda (2) · American Thrombosis and Hemostasis Network (1) · Bioverativ Therapeutics Inc. (1) · CSL Behring (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Chulalongkorn University (1) · City of Hope Medical Center (1) · Craig Seaman (1) · Dhaka Medical College (1) · Octapharma (1) · Recoly N.V. (1) · Sanofi (1)
United States (20) · Italy (16) · Spain (13) · Germany (12) · China (10) · France (10) · Russia (10) · United Kingdom (10) · Austria (9) · Bulgaria (7) · Canada (7) · Netherlands (7) · Poland (6) · Belgium (5) · Hungary (5)
Akhil R. Biswas, MBBS, FCPS (1) · Brian Feldman, MD,MSc,FRCPC (1) · Craig Seaman, MD, MS (1) · Darintr Sosothikul, Asso professer (1) · Ellis J Neufeld, MD, PhD (1) · Jack Spira, MD. PhD. (1) · Janna Journeycake, MD (1) · Nadia P Ewing, MD (1)
PMID 26931631, PMID 33269010, PMID 23528101, PMID 23750875, PMID 24227821, PMID 24843882, PMID 25196897, PMID 25855376, PMID 25952661, PMID 26663410, PMID 27002680, PMID 27330001, PMID 27339736, PMID 27436242, PMID 27577234, PMID 28220555, PMID 28836341, PMID 29296836, PMID 30013766, PMID 31697801, PMID 31778283, PMID 32197139, PMID 33719084, PMID 36192847, PMID 36626898, PMID 37309365, PMID 37538505, PMID 38371314, PMID 38853005, PMID 39091324, PMID 39667975
2008 (3), 2014 (2), 2015 (2), 2023 (2), 2005 (1), 2009 (1), 2016 (1), 2018 (1)